Introduction
The Gemtor 200 mg (Gemcitabine) Injection is a potent nucleoside analog chemotherapy agent designed to treat advanced ovarian, breast, non-small cell lung (NSCLC), pancreatic, and bladder cancers. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in oncology innovation, and supplied globally by Onco Solution, this injection disrupts cancer cell proliferation by inhibiting DNA synthesis and inducing apoptosis. With its proven efficacy in combination therapies, the Gemtor 200 mg (Gemcitabine) Injection is a critical tool for managing aggressive malignancies and improving patient outcomes.
Key Benefits
- Broad-Spectrum Efficacy: Effective against ovarian, breast, lung, pancreatic, and bladder cancers.
- Dual Mechanism: Inhibits DNA polymerase and ribonucleotide reductase, halting tumor growth.
- Combination Synergy: Enhances outcomes with carboplatin, paclitaxel, or cisplatin.
- Global Accessibility: Supplied by Onco Solution, ensuring reliable access to life-saving therapies.
Indications
The Gemtor 200 mg (Gemcitabine) Injection is indicated for:
- Ovarian Cancer: Combined with carboplatin for relapsed cases ≥6 months post-platinum therapy.
- Breast Cancer: First-line metastatic treatment with paclitaxel after anthracycline failure.
- Non-Small Cell Lung Cancer (NSCLC): Combined with cisplatin for inoperable or metastatic cases.
- Pancreatic Cancer: First-line therapy for locally advanced or metastatic adenocarcinoma.
- Bladder Cancer: Used with cisplatin in advanced stages.
Pharmacology
- Mechanism of Action:
Gemcitabine, the active ingredient in Gemtor 200 mg (Gemcitabine) Injection, is metabolized into diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. These metabolites:- Inhibit DNA Synthesis: Block ribonucleotide reductase and DNA polymerase.
- Induce Apoptosis: Trigger programmed cell death in S-phase cancer cells.
- Cell Cycle Specificity: Primarily targets cells in the S-phase, with activity at the G1-S border.
Dosage & Administration
Standard Regimens
| Indication | Dosage |
|---|---|
| NSCLC | 1000 mg/m² on days 1, 8, 15 (28-day cycle) or 1250 mg/m² on days 1, 8 (21-day cycle). |
| Pancreatic Cancer | 1000 mg/m² weekly for 7 weeks, then 3 weeks on/1 week off. |
| Ovarian Cancer | 1000 mg/m² on days 1, 8 + carboplatin (21-day cycle). |
| Breast Cancer | 1250 mg/m² on days 1, 8 + paclitaxel (21-day cycle). |
| Bladder Cancer | 1000 mg/m² on days 1, 8, 15 + cisplatin (28-day cycle). |
Administration Guidelines
- Administer via intravenous infusion over 30 minutes.
- Do not prolong infusion beyond 60 minutes (increases toxicity risk).
Drug Interactions
- Warfarin: Enhanced anticoagulant effect; monitor INR closely.
Contraindications
- Hypersensitivity to gemcitabine or components.
- Concurrent radical radiotherapy.
- Pregnancy or lactation.
Side Effects
Common Reactions:
- Hematologic: Leukopenia (60%), anemia (50%), thrombocytopenia (30%).
- Gastrointestinal: Nausea (40%), vomiting (20%), elevated transaminases (15%).
- Flu-like Symptoms: Fever (30%), fatigue (25%), muscle pain (10%).
Severe Risks:
- Myelosuppression: Life-threatening infections or bleeding (monitor CBC).
- Pulmonary Toxicity: Interstitial pneumonia, pulmonary edema (discontinue if dyspnea occurs).
- Renal Toxicity: Hemolytic uremic syndrome (HUS), proteinuria.
Pregnancy & Lactation
- Pregnancy Category D: Contraindicated due to fetal harm risk.
- Lactation: Avoid breastfeeding; potential infant toxicity.
Precautions & Warnings
- Hematologic Monitoring: Check CBC before each dose; withhold if neutrophils <1,500/mm³ or platelets <100,000/mm³.
- Renal/Hepatic Impairment: Adjust dose in severe cases; monitor creatinine/LFTs.
- Microangiopathic Anemia: Discontinue at first sign of HUS or thrombotic thrombocytopenic purpura (TTP).
Storage Conditions
- Store at 25°C; protect from light and moisture.
- Reconstituted Solution: Use immediately; discard unused portions.
Why Choose Gemtor 200 mg (Gemcitabine) Injection?
- Proven Efficacy: Clinically validated in multiple cancer types with flexible dosing.
- Quality Assurance: Produced by Eskayef Pharmaceuticals Ltd., adhering to WHO-GMP standards.
- Global Reach: Supplied by Onco Solution, ensuring equitable access across Asia, Africa, and Europe.
Conclusion
The Gemtor 200 mg (Gemcitabine) Injection is a cornerstone of modern oncology, offering targeted DNA disruption for aggressive cancers. By integrating this therapy, clinicians leverage Eskayef Pharmaceuticals Ltd.’s commitment to innovation and Onco Solution’s mission to deliver affordable, high-quality therapies worldwide.
